Type

Range

Units

Status

Start Date

End Date

Financing

Keywords

Brief description/objective

A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase
3 Study to Assess the Efficacy and Safety of Filgotinib Administered
for 24 weeks in Combination with Conventional Synthetic
Disease-modifying Anti-rheumatic Drug(s) (csDMARDs) to Subjects
with Moderately to Severely Active Rheumatoid Arthritis Who Have
an Inadequate Response to Biologic DMARD(s) Treatment